Gyre Therapeutics, Inc.
GYRE
$6.68
$0.142.14%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -12.21M | -8.69M | -1.72M | 3.61M | 2.65M |
| Total Depreciation and Amortization | 1.48M | 672.00K | 695.00K | 649.00K | 1.01M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -10.43M | 1.77M | 5.13M | 2.85M | -2.39M |
| Change in Net Operating Assets | 4.43M | 9.43M | -9.73M | -2.43M | -8.74M |
| Cash from Operations | -16.73M | 3.18M | -5.63M | 4.68M | -7.47M |
| Capital Expenditure | -262.00K | -178.00K | -144.00K | -668.00K | -335.00K |
| Sale of Property, Plant, and Equipment | 7.00K | 6.00K | 11.00K | 0.00 | 18.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 10.01M | -2.88M | 1.98M | -579.00K | 1.67M |
| Cash from Investing | 9.76M | -3.06M | 1.85M | -1.25M | 1.35M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 200.00K | 21.00K | 318.00K | 50.00K | 24.03M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -208.00K | -- | 0.00 | 315.00K | -3.79M |
| Cash from Financing | -8.00K | 21.00K | 318.00K | 365.00K | 20.25M |
| Foreign Exchange rate Adjustments | 643.00K | 285.00K | 127.00K | 117.00K | -40.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.34M | 431.00K | -3.33M | 3.91M | 14.09M |